腹腔镜远端胰腺切除术治疗胰腺导管腺癌的远期肿瘤学结局
该双机构回顾性研究纳入2002年至2016年间186例接受标准腹腔镜远端胰腺切除术的胰腺导管腺癌患者,中位总生存期32个月,5年总生存率38.2%。肿瘤>3 cm和无辅助化疗与早期复发相关,肿瘤>3 cm和淋巴血管侵犯是生存不良的独立预测因素。
要点
- 标准腹腔镜远端胰腺切除术治疗胰腺导管腺癌可获得满意的远期肿瘤学结局。
- 肿瘤>3 cm和无辅助化疗与术后6个月内早期复发相关。
- 肿瘤>3 cm和淋巴血管侵犯是复发-free生存和总生存降低的独立预测因素。
核心结论
- 标准腹腔镜远端胰腺切除术在胰腺导管腺癌患者中与满意的远期肿瘤学结局相关。
研究设计与样本
- 双机构回顾性研究,纳入2002年1月至2016年3月在挪威奥斯陆大学医院和韩国牙山医疗中心接受标准腹腔镜远端胰腺切除术的207例胰腺导管腺癌患者,排除远处转移、中转开腹和失访后186例纳入分析。
主要发现
- 中位总生存期32个月,中位无复发生存期16个月,5年总生存率估计为38.2%,5年无复发生存率估计为35.9%。
- Cox回归模型显示肿瘤>3 cm和淋巴血管侵犯是無复发生存和总生存降低的独立预测因素。
临床怎么用
- 对于接受标准腹腔镜远端胰腺切除术的胰腺导管腺癌患者,应关注肿瘤大小>3 cm、无辅助化疗和淋巴血管侵犯等预后不良因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical resection is the only curative option in patients with pancreatic ductal adenocarcinoma. Little is known about the oncologic outcomes of laparoscopic distal pancreatectomy. This bi-institutional study aimed to examine the long-term oncologic results of standard laparoscopic distal pancreatectomy in a large cohort of patients with pancreatic ductal adenocarcinoma. METHODS: From January 2002 to March 2016, 207 patients underwent standard laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma at Oslo University Hospital-Rikshospitalet (Oslo, Norway) and Asan Medical Centre (Seoul, Republic of Korea). After the exclusion criteria were applied (distant metastases at operation, conversion to an open operation, loss to follow-up), 186 patients were eligible for the analysis. Perioperative and oncologic variables were analyzed for association with recurrence and survival. RESULTS: Median overall and recurrence-free survivals were 32 and 16 months, while 5-year overall and recurrence-free survival rates were estimated to be 38.2% and 35.9%, respectively. Ninety-six (52%) patients developed recurrence: 56 (30%) extrapancreatic, 27 (15%) locoregional, and 13 (7%) combined locoregional and extrapancreatic. Thirty-seven (19.9%) patients had early recurrence (within 6 months of operation). In the multivariable analysis, tumor size >3 cm and no adjuvant chemotherapy were associated with early recurrence (P = .017 and P = .015, respectively). The Cox regression model showed that tumor size >3 cm and lymphovascular invasion were independent predictors of decreased recurrence-free and overall survival. CONCLUSION: Standard laparoscopic distal pancreatectomy is associated with satisfactory long-term oncologic outcomes in patients with pancreatic ductal adenocarcinoma. Several risk factors, such as tumor size >3 cm, no adjuvant chemotherapy, and lymphovascular invasion, are linked to poor prognosis after standard laparoscopic distal pancreatectomy.
引用
- Sahakyan MA, Kim SC, Kleive D, et al. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection. Surgery. 2017. PMID: 28756944. doi:10.1016/j.surg.2017.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。